Final five-year clinical outcomes in the EVOLVE trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent

EuroIntervention 2018;13:2047-2050 published online September 2017. DOI: 10.4244/EIJ-D-17-00529

Ian T. Meredith
Ian T. Meredith1*, AM, MBBS, PhD; Stefan Verheye2, MD, PhD; Christophe Dubois3, MD, PhD; Joseph Dens4, MD, PhD; Bruno Farah5, MD; Didier Carrié6, MD, PhD; Simon Walsh7, MD; Keith Oldroyd8, MD; Olivier Varenne9, MD, PhD; Seif El-Jack10, MBBS; Raul Moreno11, MD; Thomas Christen1, MD, PhD; Dominic J. Allocco1, MD
1. Boston Scientific Corporation, Marlborough, MA, USA; 2. Ziekenhuis Netwerk Antwerpen Middelheim, Antwerp, Belgium; 3. University Hospital Leuven, Leuven, Belgium; 4. Ziekenhuis Oost Limburg, Genk, Belgium; 5. Clinique Pasteur, Toulouse, France; 6. Univ

Aims: Long-term data on bioabsorbable polymer-coated everolimus-eluting stents (BP-EES) are limited. The EVOLVE trial compared the safety and efficacy of two dose formulations of the SYNE

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

clinical trialscoronary artery diseaseclinical research
Read next article
Clinical implications of periprocedural myocardial injury in patients undergoing percutaneous coronary intervention for chronic total occlusion: role of antegrade and retrograde crossing techniques

Latest news